sc262
Generic: HIP-modified allogeneic CD22-directed CAR T cell
sc262: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Sana Biotechnology, Inc. (SANA) | Phase 1 |
Clinical Trials (1)
A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)
Frequently asked questions
Who is developing sc262?
sc262 is being developed by Sana Biotechnology, Inc..
How many clinical trials involve sc262?
BioSniper tracks 1 clinical trial involving sc262.
Get deeper analysis on sc262
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis